Positive Results For Empagliflozin In Type 1 Diabetes Trials | Latest News RSS feed

Positive Results For Empagliflozin In Type 1 Diabetes Trials - Latest News


Recruitment begins for Oxford study testing an artificial pancreas in children with type 1 diabetes

More information on the study can be found here. Earlier this year, US researchers reported positive results from an artificial pancreas trial which led to improved blood glucose levels and fewer epis... read more

Support for add-on IDegLira in SGLT2 inhibitor-treated type 2 diabetes

medwireNews: Findings from the DUAL IX trial suggest that ... 2 inhibitor therapy results in better glycemic control than add-on insulin glargine among insulin-naïve patients with uncontrolled type 2 ... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

INGELHEIM, Germany and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials ... in adults with type 1 diabetes on empagliflo... read more

Looking for another news?


AstraZeneca announces positive results from phase III DECLARE-TIMI 58 cardiovascular outcomes trial of Farxiga to treat type-2 diabetes

AstraZeneca announced positive results from the phase III ... failure or CV death in a broad range of patients with type-2 diabetes and cardiovascular risk. The results from this landmark trial are es... read more


Johnson & Johnson's Type 2 Diabetes Drug Is Stellar in Cardiovascular Trials, but Comes With a Catch

Healthcare conglomerate Johnson & Johnson's (NYSE: JNJ) long-awaited data from Invokana, its type 2 diabetes blockbuster drug ... Overall, though, these results suggest Invokana is a positive for a va... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomised controlled trials ... empagliflozin 2.5 mg and placebo and higher than placebo in adults with type 1 dia... read more

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

and INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) today announced that both randomized controlled trials ... in adults with type 1 diabetes on empagl... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us